Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25657144 | 0.84 | TSHR (0.66) | TSHRSRCCETPKDM4EALDH1A1 | |
| SCHEMBL11538617 | 0.84 | TSHR (0.70) | TSHRSRCCETPKDM4EALDH1A1 | |
| SCHEMBL25657182 | 0.80 | TSHR (0.64) | TSHRSRCCETPKDM4EALDH1A1 | |
| SCHEMBL20701826 | 0.79 | TSHR (0.79) | TSHRSRCCETPKDM4EALDH1A1 | |
| SCHEMBL22066048 | 0.78 | TSHR (0.66) | TSHRSRCCETPKDM4EALDH1A1 | |
| SCHEMBL51316 | 0.78 | TSHR (1.00) | TSHRSRCCETPALDH1A1FOLH1 | |
| SCHEMBL27908642 | 0.78 | TSHR (1.00) | TSHRSRCCETPALDH1A1FOLH1 | |
| SCHEMBL25657175 | 0.78 | TSHR (0.60) | TSHRSRCCETPKDM4EALDH1A1 | |
| SCHEMBL17516308 | 0.78 | TSHR (0.60) | TSHRSRCCETPKDM4EALDH1A1 | |
| SCHEMBL23084624 | 0.78 | TSHR (0.70) | TSHRSRCCETPKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | TSHR 3245/4885SRC 1510/4885CETP 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.